We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
-33.22%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$103M
AUM Growth
–
Cap. Flow
+$147M
Cap. Flow %
143.07%
Top 10 Hldgs %
97.57%
Holding
13
New
13
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 quarters
Top 10 Avg Time Held
0 quarters
Top 20 Avg Time Held
0 quarters

Top Buys

Rank Stock Value
1
LVGO
Livongo Health, Inc. Common Stock
LVGO
+$79.7M
2
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$41.7M
3
DTIL icon
Precision BioSciences
DTIL
+$11.8M
4
OVID icon
Ovid Therapeutics
OVID
+$1.65M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$1.64M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 55.23%
2 Communication Services 44.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
LVGO
1
DELISTED
Livongo Health, Inc. Common Stock
LVGO
$46M 44.77%
+2,636,640
New +$79.7M
2019 Q3
0 quarters
ORTX
2
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$35.5M 34.58%
+299,021
New +$41.7M
2019 Q3
0 quarters
DTIL icon
3
Precision BioSciences
DTIL
$178M
$9.09M 8.85%
+36,126
New +$11.8M
2019 Q3
0 quarters
OVID icon
4
Ovid Therapeutics
OVID
$477M
$2.36M 2.29%
+727,260
New +$1.65M
2019 Q3
0 quarters
GBT
5
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.36M 1.32%
+28,000
New +$1.46M
2019 Q3
0 quarters
BPMC icon
6
DELISTED
Blueprint Medicines
BPMC
$1.32M 1.29%
+18,000
New +$1.56M
2019 Q3
0 quarters
CRVS icon
7
Corvus Pharmaceuticals
CRVS
$848M
$1.18M 1.14%
+390,307
New +$1.64M
2019 Q3
0 quarters
MYOK
8
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$1.17M 1.14%
+22,464
New +$1.19M
2019 Q3
0 quarters
COGT icon
9
Cogent Biosciences
COGT
$5.24B
$1.14M 1.11%
+197,701
New +$1.61M
2019 Q3
0 quarters
BLUE icon
10
DELISTED
bluebird bio
BLUE
$1.1M 1.07%
+926
New +$1.41M
2019 Q3
0 quarters
RARE icon
11
Ultragenyx Pharmaceutical
RARE
$1.5B
$1.03M 1%
+24,000
New +$1.3M
2019 Q3
0 quarters
BOLD icon
12
DELISTED
Audentes Therapeutics, Inc
BOLD
$983K 0.96%
+35,000
New +$1.19M
2019 Q3
0 quarters
KZR icon
13
DELISTED
Kezar Life Sciences
KZR
$486K 0.47%
+14,809
New +$715K
2019 Q3
0 quarters

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q3 2019 Portfolio in Review

Q3 2019 is the first quarter with a 13F filing on record for CHI Advisors, which disclosed 13 positions worth $103M. Its ten largest holdings account for 98% of the portfolio.

Its largest position is Livongo Health, Inc. Common Stock: 2,636,640 shares worth $46M.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, followed by Communication Services.

  • CHI Advisors's largest Q3 2019 buy was Livongo Health, Inc. Common Stock: 2,636,640 shares worth $46M.
  • CHI Advisors's ten largest holdings make up 98% of its $103M portfolio in Q3 2019.
  • CHI Advisors disclosed 13 positions in Q3 2019, its first 13F filing on record.

Based on CHI Advisors's 13F filing for Q3 2019, filed 12 Nov 2019.